Nanologica AB (DE:4YD)
FRANKFURT:4YD
4YD Stock Chart & Stats
€0.04
<€0.01(1.49%)
At close: 4:00 PM EST
€0.04
<€0.01(1.49%)
Day’s Range― - ―
52-Week Range€0.03 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€11.26M
Enterprise Value€51.46M
Total Cash (Recent Filing)€3.55M
Total Debt (Recent Filing)€21.68M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding328,769,840
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€7.79M
Bulls Say, Bears Say
Bulls Say
Pharma-focused Consumable ProductNanologica supplies silica-based separation media used in drug purification and chromatography — a structural demand driver as pharma R&D and manufacturing require reliable consumables. Consumable use creates recurring purchase potential and customer stickiness across labs and production workflows, supporting durable revenue streams if product performance and regulatory acceptance remain strong.
Revenue Scale ImprovementTop-line growth to SEK 21.1M from SEK 14.5M shows the business can scale sales despite volatility. A larger revenue base supports potential operating leverage and better absorption of fixed costs over the medium term, improving the path toward margin recovery if gross-profit drivers (pricing, mix, yields) can be improved.
Manageable Documented LeverageReported debt levels (~21.7M) relative to equity (~22.6M) indicate leverage that is not extreme for an R&D/manufacturing firm. This provides some short-term financial flexibility and reduces immediate insolvency risk compared with highly leveraged peers, giving management time to improve operations or secure incremental financing on more orderly terms.
Bears Say
Negative Gross Profit And LossesSustained negative gross profit indicates the core product economics are currently unprofitable. Without durable improvement to yields, pricing, or cost structure, the company cannot generate positive operating margins. Over a multi-month horizon this undermines self-sustainability and forces reliance on external financing or structural business changes to survive.
High Cash Burn And Negative FCFLarge negative operating and free cash flows show the company is consuming capital to run current operations. Even with year-over-year improvement, ongoing FCF deficits limit the ability to invest in scale or R&D organically and create persistent funding needs. This raises dilution and financing risk over the medium term until cash generation turns positive.
Eroded Equity BaseA materially reduced equity cushion shrinks the company’s ability to absorb further losses and increases the probability of future capital raises. Reduced equity heightens refinancing and covenant risk, and weakens bargaining power with lenders and partners, making the company more vulnerable during prolonged operating headwinds.
Nanologica AB News
4YD FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was €0.03 and its highest was €0.15 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is €11.26M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is May 20, 2026 which is in 43 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Feb 26, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of -€0.009 by -€0.008.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -€0.017 in its last earnings report, missing expectations of -€0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in DE:4YD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―